Cargando…

Considerations and Challenges in the Management of the Older Patients with Gastric Cancer

SIMPLE SUMMARY: Older patients diagnosed with gastric cancer represent a significant proportion of patients with the disease. These patients can range from extremely fit to very frail and can have different expectations and goals from their younger counterparts. Currently there is little evidence av...

Descripción completa

Detalles Bibliográficos
Autores principales: Loizides, Sotiris, Papamichael, Demetris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946244/
https://www.ncbi.nlm.nih.gov/pubmed/35326739
http://dx.doi.org/10.3390/cancers14061587
Descripción
Sumario:SIMPLE SUMMARY: Older patients diagnosed with gastric cancer represent a significant proportion of patients with the disease. These patients can range from extremely fit to very frail and can have different expectations and goals from their younger counterparts. Currently there is little evidence available in the literature to guide management. The design of clinical trials specific to this age group is therefore urgently needed. In the meantime, these patients should undergo some form of geriatric screening when managed during routine clinical practice. ABSTRACT: Gastric cancer is one of the commonest malignancies with high rates of mortality worldwide. Older patients represent a substantial proportion of cases with this diagnosis. However, there are very few ‘elderly-specific’ trials in this setting. In addition, the inclusion rate of such patients in randomised clinical trials is poor, presumably due to concerns about increased toxicity, co-existing comorbidities and impaired performance status. Therapeutic strategies for this patient group are therefore mostly based on retrospective subgroup analysis of randomised clinical trials. Review of currently available evidence suggests that older gastric cancer patients who are fit for trial inclusion may benefit from surgical intervention and peri-operative systemic chemotherapy strategies. For patients with metastatic disease, management has been revolutionized by the use of anti-HER2 directed therapies as well as immune checkpoint inhibitors with or without chemotherapy. Early data suggest that fit older patients may also benefit from these therapeutic interventions. However, once again there may be limitations in extrapolating these data to everyday clinical practice with older patients being less likely to have a good performance status and an intact immune system. Therefore, determining the functional age and not just the chronological age of a patient prior to initiating therapy becomes very important. The functional decline including reduced organ function that may occur in older patients makes the integration of some form of geriatric assessment in routine clinical practice very relevant.